MBX Biosciences, Inc. (MBX)
NasdaqGS · USD · Healthcare · Biotechnology
$50.63 (+0.67%) as of
Key statistics
- Market cap
- 2.44B
- Forward P/E
- -12.73
- EPS (TTM)
- -2.37
- Dividend yield
- 0.00%
- 52-week range
- 16.95 – 72.64
- Beta
- 0.10
- Profit margin
- 0.00%
- Analyst target
- $95.70
- Volume
- 15.38k
About MBX Biosciences, Inc.
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Carmel, IN, United States
- Employees
- 63
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.